Sitewide Sale: Create a Free Seeking Alpha Account
Join the world's leading investor community and get 20% off your first year of any Seeking Alpha service.

or
By creating an account using any of the options above, you agree to the Terms of Use & Privacy Policy

ETNB 89bio, Inc.
Stock Price & Overview

$9.82-0.04 (-0.41%)4:00 PM 06/30/25
NASDAQ | $USD | Post-Market: $9.69 -0.13 (-1.32%) 7:52 PM

ETNB Stock Price

EPS
PE
Div Rate
Yield
Short Interest
Market Cap
Volume
Prev. Close
Expand For Key Data »

Quant Ranking

ETNB Analysis

See All Analysis »

ETNB News

See All News »

Latest Headlines

Ratings Summary

People Also Follow

Similar to ETNB

ETFs Holding ETNB

ETNB Company Profile

89bio, Inc. logo
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California.
Sector
Health Care
Industry
Biotechnology
Employees
93
Founded
2018
Address
  • 655 Montgomery Street
  • Suite 1500
  • San Francisco, CA, 94111
  • United States
Phone Number
415 432 9270
Website
www.89bio.com
Hide

ETNB Revenue

More On Revenue »

ETNB Earnings Per Share

More On Earnings »

Earnings Estimates

Earnings Revisions

Valuation

Profitability

Momentum

Capital Structure

Dividends

ETNB does not currently pay a dividend.

ETNB Ownership

ETNB Peers

Risk

Technicals

Investor Presentations

ETNB SEC Filings

See All SEC Filings »

Press Releases

See All Press Releases »

ETNB Income Statement

ETNB Balance Sheet

ETNB Cash Flow Statement

ETNB Long Term Solvency

89bio, Inc. (ETNB) Frequently Asked Questions